Home » Five Firms Big Pharma Should Buy Next
Five Firms Big Pharma Should Buy Next
Pharmaceutical companies still
see riches in biotechnology. AstraZeneca's $15.6 billion deal to acquire MedImmune
is only the latest example of their continuing willingness to pay high premiums
(in this case, a 53% premium to where MedImmune was trading before it put itself
up for sale) for future growth.
Yahoo
Finance
KEYWORDS biotech
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May